Deepak Bhatt, MD, MPH, offers his thoughts on the results of SCORED and SOLOIST as well as diving deeper into the implications of the data for sotagliflozin and SGLT2 inhibitors moving forward.
Among the thousands of studies presented at the American Heart Association’s Scientific Sessions 2020 were a pair of late-breaking studies presented by Deepak Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital. Titled SCORED and SOLOIST, the pair of phase 3 trials examined use of sotagliflozin in patients with type 2 diabetes and worsening heart failure or chronic kidney disease.
While diabetes medications have stolen headlines at major cardiovascular meetings in the past few years, sotagliflozin sets itself apart from dapagliflozin and empagliflozin as the only dual SGLT2/1 inhibitor currently in development for treatment of type 1 and type 2 diabetes. As part of Practical Cardiology’s coverage of the annual conference, we reached out to Bhatt for further insight into the results of SOLOIST and SCORED—that conversation Is the subject of this special edition AHA 2020 House Call.